Last reviewed · How we verify

racemic salbutamol — Competitive Intelligence Brief

racemic salbutamol (racemic salbutamol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-2 adrenergic receptor agonist (short-acting). Area: Respiratory.

marketed Beta-2 adrenergic receptor agonist (short-acting) ADRB2 (beta-2 adrenergic receptor) Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

racemic salbutamol (racemic salbutamol) — University of Dundee. Racemic salbutamol is a non-selective beta-2 adrenergic receptor agonist that relaxes airway smooth muscle and increases bronchial airflow.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
racemic salbutamol TARGET racemic salbutamol University of Dundee marketed Beta-2 adrenergic receptor agonist (short-acting) ADRB2 (beta-2 adrenergic receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-2 adrenergic receptor agonist (short-acting) class)

  1. University of Dundee · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). racemic salbutamol — Competitive Intelligence Brief. https://druglandscape.com/ci/racemic-salbutamol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: